Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Henning Olbrich; Christian D. Sadik; Ralf J. Ludwig; Diamant Thaçi; Katharina Boch

doi:10.3390/biom13040634

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Henning Olbrich^*, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaçi, Katharina Boch

^*Korrespondierende/r Autor/-in für diese Arbeit

5 Zitate (Scopus)

Abstract

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

Originalsprache	Englisch
Aufsatznummer	634
Zeitschrift	Biomolecules
Jahrgang	13
Ausgabenummer	4
ISSN	2218-273X
DOIs	https://doi.org/10.3390/biom13040634
Publikationsstatus	Veröffentlicht - 04.2023

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Zentren: Center for Research on Inflammation of the Skin (CRIS)

DFG-Fachsystematik

2.21-05 Immunologie
2.22-19 Dermatologie
2.22-22 Klinische Immunologie und Allergologie

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.3390/biom13040634

Weitere Links

SFB 1526, PANTAU: Pathomechanismen Antikörpervermittelter Autoimmunerkrankungen
Sadik, C. (Sprecher*in, Koordinator*in), Zillikens, D. (Sprecher*in, Koordinator*in), Scheffold, A. (Projektleiter*in (PI)), Schmidt, E. (Projektleiter*in (PI)), Heine, G. (Projektleiter*in (PI)), Manz, R. (Projektleiter*in (PI)), Köhl, J. (Projektleiter*in (PI)), Ludwig, R. (Projektleiter*in (PI)), Peipp, M. (Projektleiter*in (PI)), Hammers, M. C. (Projektleiter*in (PI)), Verschoor, A. (Projektleiter*in (PI)), Karsten, C. (Projektleiter*in (PI)), Nimmerjahn, F. (Projektleiter*in (PI)), Hutloff, A. (Projektleiter*in (PI)), Ibrahim, S. (Projektleiter*in (PI)), Wettschureck, N. (Projektleiter*in (PI)), Bieber, K. (Projektleiter*in (PI)), Schilf, P. (Projektleiter*in (PI)), Vaeth, M. (Projektleiter*in (PI)), Hirose, M. (Projektleiter*in (PI)), Vaeth, M. (Projektleiter*in (PI)), Baines, J. F. (Projektleiter*in (PI)), Bacher, P. (Projektleiter*in (PI)), Hoffmann, M. (Projektleiter*in (PI)), Busch, H. S. (Projektleiter*in (PI)), Höppner, M. (Projektleiter*in (PI)), Becker, M. (Projektleiter*in (PI)), Holtsche, M. M. (Projektleiter*in (PI)), Fähnrich, A. (Projektleiter*in (PI)), Szymczak, S. (Projektleiter*in (PI)), Murthy, S. (Projektleiter*in (PI)) & Lux, A. (Projektleiter*in (PI))
01.01.22 → …
Projekt: DFG-Projekte › DFG-Verbundforschung: Sonderforschungsbereiche/ Transregios

Zitieren

@article{5e5e98c3f1c0419a84f90281ce6d1179,

title = "Dupilumab in Inflammatory Skin Diseases: A Systematic Review",

abstract = "Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.",

author = "Henning Olbrich and Sadik, {Christian D.} and Ludwig, {Ralf J.} and Diamant Tha{\c c}i and Katharina Boch",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

doi = "10.3390/biom13040634",

language = "English",

volume = "13",

journal = "Biomolecules",

issn = "2218-273X",

number = "4",

}

TY - JOUR

T1 - Dupilumab in Inflammatory Skin Diseases

T2 - A Systematic Review

AU - Olbrich, Henning

AU - Sadik, Christian D.

AU - Ludwig, Ralf J.

AU - Thaçi, Diamant

AU - Boch, Katharina

PY - 2023/4

Y1 - 2023/4

N2 - Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

AB - Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

UR - http://www.scopus.com/inward/record.url?scp=85156159006&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/bcd6ff5f-947d-32a2-b6c2-68d2f8943fa8/

U2 - 10.3390/biom13040634

DO - 10.3390/biom13040634

M3 - Scientific review articles

C2 - 37189381

AN - SCOPUS:85156159006

SN - 2218-273X

VL - 13

JO - Biomolecules

JF - Biomolecules

IS - 4

M1 - 634

ER -

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Abstract

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

UN SDGs

Dokumente

Weitere Links

Fingerprint

Projekte

SFB 1526, PANTAU: Pathomechanismen Antikörpervermittelter Autoimmunerkrankungen

Zitieren